S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
S&P 500   3,852.36
DOW   32,920.46
QQQ   293.34
Mullen Automotive: The Good News, The Bad And The Ugly Outlook 
Is This The End of Capitalism? (Ad)
A Non-Salesy Annuity Guide To Buying Annuities
3 Small Caps That Have Big Upside
Is This The End of Capitalism? (Ad)
Levi Strauss Is A Good Fit For Income Investors 
What Does Apple's Move to India Mean for Investors?
Is This The End of Capitalism? (Ad)
Mergers and Acquisitions in 2023 Off To A Strong Start
Chevron Delights Shareholders with $75 Billion in Share Buybacks
NASDAQ:SRRK

Scholar Rock - SRRK Stock Forecast, Price & News

$12.52
+0.19 (+1.54%)
(As of 01/26/2023 12:00 AM ET)
Add
Compare
Today's Range
$12.19
▼
$12.71
50-Day Range
$7.51
▼
$12.72
52-Week Range
$4.32
▼
$21.17
Volume
154,705 shs
Average Volume
350,864 shs
Market Capitalization
$646.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.67

Scholar Rock MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
105.0% Upside
$25.67 Price Target
Short Interest
Bearish
5.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
0.93mentions of Scholar Rock in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$455,061 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

341st out of 1,048 stocks

Biological Products, Except Diagnostic Industry

55th out of 168 stocks

See Top Rated MarketRank™ Stocks Here

SRRK stock logo

About Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Stock News Headlines

January 26, 2023 | americanbankingnews.com
Scholar Rock (NASDAQ:SRRK) Trading Up 4.2%
January 11, 2023 | seekingalpha.com
Scholar Rock Holding (SRRK) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow
January 27, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 11, 2023 | nypost.com
Calling all NY high school students: Enter the New York Post Scholars Contest
January 9, 2023 | finance.yahoo.com
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023
January 3, 2023 | finance.yahoo.com
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference
November 16, 2022 | finance.yahoo.com
Scholar Rock Holding Third Quarter 2022 Earnings: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)
November 14, 2022 | finance.yahoo.com
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
January 27, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
November 10, 2022 | finance.yahoo.com
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
November 9, 2022 | finance.yahoo.com
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
October 30, 2022 | msn.com
Over $1 Million Bet On Scholar Rock Holding? 3 Stocks Insiders Are Buying
October 28, 2022 | benzinga.com
1.05M Reasons To Be Bullish On Scholar Rock Holding Stock
October 22, 2022 | finance.yahoo.com
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA
October 20, 2022 | seekingalpha.com
Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy
October 18, 2022 | nasdaq.com
Scholar Rock Holding (NASDAQ:SRRK) shareholders have endured a 73% loss from investing in the stock a year ago
October 6, 2022 | finance.yahoo.com
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting
October 4, 2022 | finance.yahoo.com
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy
October 3, 2022 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Scholar Rock Holding (SRRK)
September 23, 2022 | finance.yahoo.com
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 21, 2022 | seekingalpha.com
Jay Backstrom is the new CEO at Scholar Rock
September 20, 2022 | finance.yahoo.com
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer
September 19, 2022 | finance.yahoo.com
Analyst Builds Bullish Case For This Neuromuscular Company, Sees 200% Upside
September 19, 2022 | markets.businessinsider.com
Expert Ratings for Scholar Rock Holding
September 16, 2022 | finance.yahoo.com
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
September 4, 2022 | finance.yahoo.com
Investors in Scholar Rock Holding (NASDAQ:SRRK) have unfortunately lost 75% over the last year
August 14, 2022 | seekingalpha.com
Scholar Rock Holding (SRRK) Investor Presentation - Slideshow
See More Headlines
Receive SRRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

SRRK Company Calendar

Last Earnings
11/14/2022
Today
1/27/2023
Next Earnings (Estimated)
3/06/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRK
CUSIP
N/A
CIK
1727196
Web
www.scholarrock.com
Phone
(857) 259-3860
Fax
866-493-4935
Employees
145
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.67
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+105.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-131,800,000.00
Net Margins
N/A
Pretax Margin
-352.19%
Return on Equity
-54.30%
Return on Assets
-37.88%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
10.60
Quick Ratio
10.60

Sales & Book Value

Annual Sales
$18.82 million
Price / Sales
34.37
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.90 per share
Price / Book
2.56

Miscellaneous

Outstanding Shares
51,660,000
Free Float
50,604,000
Market Cap
$646.78 million
Optionable
Not Optionable
Beta
0.64

Key Executives

  • Mr. Edward H. Myles M.B.A.Mr. Edward H. Myles M.B.A. (Age 51)
    MBA, CFO, COO & Treasurer
    Comp: $615.87k
  • Dr. Jay T. Backstrom M.D. (Age 67)
    M.P.H., Pres, CEO & Director
  • Ms. Catherine Hu
    VP of Investor Relations & Corp. Communications
  • Ms. Junlin Ho J.D. (Age 44)
    Gen. Counsel & Corp. Sec.
  • Ms. Caryn Parlavecchio (Age 51)
    Chief HR Officer
  • Ms. Lisa Amaya Price
    Sr. VP of HR
  • Dr. George G. Nomikos M.D.
    Ph.D., Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area
  • Ms. Erin Moore (Age 48)
    Sr. VP of Fin.
  • Mr. Ryan Iarrobino
    Sr. VP of Clinical Devel. & Operations
  • Dr. Jing L. Marantz M.B.A. (Age 58)
    M.D., Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SRRK Stock - Frequently Asked Questions

Should I buy or sell Scholar Rock stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRRK shares.
View SRRK analyst ratings or view top-rated stocks.

What is Scholar Rock's stock price forecast for 2023?

5 equities research analysts have issued 1-year target prices for Scholar Rock's stock. Their SRRK share price forecasts range from $19.00 to $33.00. On average, they anticipate the company's stock price to reach $25.67 in the next year. This suggests a possible upside of 105.0% from the stock's current price.
View analysts price targets for SRRK or view top-rated stocks among Wall Street analysts.

How have SRRK shares performed in 2023?

Scholar Rock's stock was trading at $9.05 at the start of the year. Since then, SRRK shares have increased by 38.3% and is now trading at $12.52.
View the best growth stocks for 2023 here.

When is Scholar Rock's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our SRRK earnings forecast.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) posted its earnings results on Monday, November, 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.13.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $12.52.

How much money does Scholar Rock make?

Scholar Rock (NASDAQ:SRRK) has a market capitalization of $646.82 million and generates $18.82 million in revenue each year. The company earns $-131,800,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis.

How many employees does Scholar Rock have?

The company employs 145 workers across the globe.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.scholarrock.com. The company can be reached via phone at (857) 259-3860, via email at chu@scholarrock.com, or via fax at 866-493-4935.

This page (NASDAQ:SRRK) was last updated on 1/27/2023 by MarketBeat.com Staff